Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giorgio Minotti

Showing results (41-50 of 130) with videos related to

Pageof 13
Sort By:
Topics in Current Chemistry|April 23, 2013
Anthracycline cardiotoxicityPierantonio Menna, Emanuela Salvatorelli, Luca Gianni, et al.
Free Radical Biology & Medicine|June 12, 2002
The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damageGaetano Cairo, Stefania Recalcati, Antonello Pietrangelo, et al.
Leukemia|December 2, 2025
Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinibAlessandra Tedeschi, Anna Maria Frustaci, Pierantonio Menna, et al.
Leukemia|October 2, 2025
Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinibAlessandra Tedeschi, Anna Maria Frustaci, Pierantonio Menna, et al.
Leukemia|November 3, 2025
Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinibAlessandra Tedeschi, Anna Maria Frustaci, Pierantonio Menna, et al.
JACC. Cardiooncology|May 2, 2022
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational ApproachGiorgio Minotti, Giorgio Reggiardo, Massimiliano Camilli, et al.
Expert Review of Hematology|June 19, 2018
Pixantrone: novel mode of action and clinical readoutsGiorgio Minotti, Haiyong Han, Valérie Cattan, et al.
European Cardiology|October 20, 2025
Adjudication of Adverse Cardiovascular Events in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib: Deaths in GLOW or Blowing in the Wind?Roberta Esposito, Pierantonio Menna, Emanuela Salvatorelli, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 10, 2017
Low-Dose Anthracycline and Risk of Heart Failure in a Pharmacokinetic Model of Human Myocardium Exposure: Analog Specificity and Role of Secondary Alcohol MetabolitesEmanuela Salvatorelli, Pierantonio Menna, Massimo Chello, et al.
Advances in Pharmacology (San Diego, Calif.)|June 6, 2022
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncologyGiorgio Minotti, Pierantonio Menna, Massimiliano Camilli, et al.
Pageof 13

Showing results (41-50 of 130) with videos related to

Sort By:
Pageof 13
Topics in Current Chemistry|April 23, 2013
Anthracycline cardiotoxicityPierantonio Menna, Emanuela Salvatorelli, Luca Gianni, et al.
Free Radical Biology & Medicine|June 12, 2002
The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damageGaetano Cairo, Stefania Recalcati, Antonello Pietrangelo, et al.
Leukemia|December 2, 2025
Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinibAlessandra Tedeschi, Anna Maria Frustaci, Pierantonio Menna, et al.
Leukemia|October 2, 2025
Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinibAlessandra Tedeschi, Anna Maria Frustaci, Pierantonio Menna, et al.
Leukemia|November 3, 2025
Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinibAlessandra Tedeschi, Anna Maria Frustaci, Pierantonio Menna, et al.
JACC. Cardiooncology|May 2, 2022
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational ApproachGiorgio Minotti, Giorgio Reggiardo, Massimiliano Camilli, et al.
Expert Review of Hematology|June 19, 2018
Pixantrone: novel mode of action and clinical readoutsGiorgio Minotti, Haiyong Han, Valérie Cattan, et al.
European Cardiology|October 20, 2025
Adjudication of Adverse Cardiovascular Events in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib: Deaths in GLOW or Blowing in the Wind?Roberta Esposito, Pierantonio Menna, Emanuela Salvatorelli, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 10, 2017
Low-Dose Anthracycline and Risk of Heart Failure in a Pharmacokinetic Model of Human Myocardium Exposure: Analog Specificity and Role of Secondary Alcohol MetabolitesEmanuela Salvatorelli, Pierantonio Menna, Massimo Chello, et al.
Advances in Pharmacology (San Diego, Calif.)|June 6, 2022
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncologyGiorgio Minotti, Pierantonio Menna, Massimiliano Camilli, et al.
Pageof 13